Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
Open Access
- 14 June 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (9) , 4169-4175
Abstract
Acne‐like skin reactions frequently occur in patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor. Recently, the effects of vitamin K1 containing cream (Reconval K1) as prophylactic skin treatment in addition to doxycycline were explored in a double‐blind randomized phase II trial (EVITA) in patients with metastatic colorectal cancer receiving cetuximab. EVITA demonstrated a trend towards less severe skin rash in Reconval K1‐treated patients using the tripartite WoMo skin reaction grading score as a thorough tool for quantification of drug related skin reactions. This gender‐specific analysis of the EVITA trial evaluated the application of the WoMo score for assessment of epidermal growth factor receptor (EGFR)‐related skin toxicities according to treatment arm and gender. To show the robustness of results parametric and non‐parametric statistical analyses were conducted. All three parts of the WoMo score independently demonstrated the superiority of the treatment arm (Reconval K1) regarding a significant reduction in acneiform skin reactions in women. Men did not benefit from Reconval K1 cream at any time point in none of the WoMo score analyses. The treatment effect in women was confirmed by the use of skin rash categories based on the final WoMo overall score and mixed effect longitudinal multiple linear regression analysis. The WoMo score represents a sensitive tool for studies exploiting treatments against EGFR mediated acne‐like skin rash. Part C of the WoMo score seems to be sufficient for quantification of drug related skin toxicities in further studies. Standard WoMo skin reaction score values for future studies are provided.Keywords
Funding Information
- Merck KGaA
- Deutsche Forschungsgemeinschaft (259332240 / RTG 2099)
This publication has 13 references indexed in Scilit:
- Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitorsCritical Reviews in Oncology/Hematology, 2017
- Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid TumorsThe Oncologist, 2016
- Transport efficiency in transdermal drug delivery: What is the role of fluid microstructure?Colloids and Surfaces B: Biointerfaces, 2016
- Patterns of sunscreen use on the face and other exposed skin among US adultsJournal of the American Academy of Dermatology, 2015
- Randomized Controlled Trial on the Skin Toxicity of Panitumumab in Japanese Patients with Metastatic Colorectal Cancer: HGCSG1001 Study; J-STEPPFuture Oncology, 2015
- The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and CetuximabClinical Cancer Research, 2011
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibitionExperimental Dermatology, 2008
- Constructions of masculinity and their influence on men's well-being: a theory of gender and healthSocial Science & Medicine, 2000
- Hormone Epidermal Growth Factor Interactions in DevelopmentHormone Research, 1990